Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation.
Spitzer
T R
TR
Bone Marrow Transplantation Program, Lombardi Cancer Research Center, Georgetown University Hospital, Washington, DC 20007.
Cottler-Fox
M
M
Sullivan
P
P
Lynch
M
M
Tefft
M C
MC
Pickle
L W
LW
Cirenza
E
E
Cahill
R
R
Deeg
H J
HJ
Sacher
R
R
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000097:blood*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D015994:Incidence; D017053:Infection Control / Q000379:methods*; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous